Results 141 to 150 of about 20,376 (259)

Understanding Diabetes Distress: A Study of Contributing Factors Among Adults With Type 2 Diabetes in Rural East Godavari, Andhra Pradesh. [PDF]

Cureus
Meka RJ, Sundaram M S, Rani K S G, Mani V, Natrajan M.   +4 more
europepmc   +1 more source

Identifying high-risk combinations of metformin during COVID-19. [PDF]

PLoS One
Dimnjaković J, Buble T, Poljičanin T, Brborović H, Brađašević E, Brborović O.   +5 more
europepmc   +1 more source

Mechanism‐Informed Pharmacotherapy Optimization and Deprescribing: A Redox–Mitochondrial Framework

Pharmacology Research &Perspectives, Volume 14, Issue 5, October 2026.
From cumulative drug burden to mitochondrial stress and functional decline. The graphical abstract summarizes the central concept of the review, illustrating how cumulative pharmacotherapy exposure may contribute to redox–mitochondrial stress and thereby reduce biological and functional resilience.
Boštjan Martinc
wiley   +1 more source

Evaluation of %CV and average glucose derived from pre- and postprandial 6-point glucose measurements for assessing hypoglycemia risk. [PDF]

J Diabetes Investig
Soga R, Torimoto K, Uemura F, Okada Y, Nakayamada S.   +4 more
europepmc   +1 more source

Type 5 Diabetes Mellitus: Pathophysiology, Clinical Phenotype, and Nutritional Management

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.
ABSTRACT Type 5 Diabetes Mellitus (T5DM) is an emerging diabetes phenotype linked to chronic undernutrition. It predominantly affects young, lean individuals in low‐ and middle‐income countries. After its formal recognition by the International Diabetes Federation in 2025, T5DM resurfaced as a clinically relevant insulin‐deficient phenotype.
İrem Nur Şahin Anılgan, Aslıhan Atar‐Uğurlu   +1 more
wiley   +1 more source

The Impact of Polymers in Amorphous Solid Dispersion on the Bioavailability of Sulfonylureas and Meglitinides. [PDF]

Drug Des Devel Ther
Aulifa DL, Wibisono TTDW, Ningsih JD, Christy GDAB, Pertiwi DS, Praja HM, Gazzali AM, Amaliah S, Budiman A.   +8 more
europepmc   +1 more source

Effects of Oral Semaglutide on Dietary Intake and Body Composition in Japanese People With Type 2 Diabetes: A Prospective Observational Study in Clinical Practice

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
This prospective observational study evaluated changes in dietary patterns and body composition after 3 months of oral semaglutide treatment in people with Type 2 diabetes. Oral semaglutide was associated with reduced energy intake, salt intake and body fat while preserving handgrip strength.
Mika Sawada, Naoko Nakanishi, Masakazu Aihara, Kanako Ohkuma, Shoko Hamano, Yoshitaka Sakurai, Rie Sekine, Satoshi Usami, Toshimasa Yamauchi, Naoto Kubota   +9 more
wiley   +1 more source

Discovery of novel quinazoline-sulfonamide derivatives with promising antidiabetic activity. [PDF]

Front Chem
Zayed MF, Muhammad Y, Alqurain AA, Banafa MAA, Omar AM.   +4 more
europepmc   +1 more source

Dipeptidyl Peptidase‐4 Inhibitors Associated Heart Failure Events in Adult Patients With Type‐2 Diabetes Mellitus Treated With Dipeptidyl Peptidase‐4 Inhibitors: A Systematic Review and Meta‐Analysis

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 5, September 2026.
DPP‐4 Inhibitors associated withheart failure events in patients with type‐2 diabetes. This study found statistically insignificant summary effect for all DPP‐4 inhibitors combined but found asignificant association of saxagliptin with heart failure events (RR = 1.24, 95% CI 1.05–1.47). Results are to be interpreted with caution.
Shishir Nepal, Shiva Prasad Nepal
wiley   +1 more source

Predictors of Glycemic Response to Sulfonylurea Therapy in Type 2 Diabetes Over 12 Months: Comparative Analysis of Linear Regression and Machine Learning Models. [PDF]

JMIR Diabetes
Garg S, Kitchen R, Gupta R, Trucco E, Pearson E.   +4 more
europepmc   +1 more source